Jonathan Goldman

Jonathan Goldman

Directeur Général chez
Clinical Ink, Inc.

Fortune : 50 498 $ au 31/05/2026

61 ans
Health Technology
Consumer Services
Finance

Profil

Jonathan H.
Goldman
is currently Chief Executive Officer at Clinical Ink, Inc. since 2023.
Dr. Goldman is also a Director at Quadria Capital Investment Management Pte Ltd. and a Director at Astro Bidco Ltd. since 2018.
Former roles include Chief Executive Officer, Director & MD at Abzena Ltd. from 2018 to 2022, Chief Executive Officer at Aptuit LLC, Independent Director at Avalo Therapeutics, Inc. from 2024 to 2026, Chief Medical Officer & VP-Medical Affairs at POINT Biomedical Corp., Operating Partner at Welsh, Carson, Anderson & Stowe, and Associate Clinical Professor-Medicine at The University of California, San Francisco.
Education includes an MBA from The Trustees of Columbia University in The City of New York, undergraduate and doctorate degrees from the University of London, and an MBA from the University of California, Berkeley.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
28/03/2026 3 166 ( 0,01% ) 50 498 $ 31/05/2026

Postes actifs de Jonathan Goldman

SociétésPosteDébut
Directeur/Membre du Conseil 13/08/2018
Directeur Général 13/02/2023
Private Equity Investor -

Anciens postes connus de Jonathan Goldman

SociétésPosteFin
AVALO THERAPEUTICS, INC. Directeur/Membre du Conseil 02/06/2026
ABZENA PLC Directeur Général 13/10/2022
Corporate Officer/Principal -
Private Equity Investor -
Directeur Général -
Voir l'expérience en détail de Jonathan Goldman

Formation de Jonathan Goldman

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

15

Relations au 1er degré

12

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées12

Health Technology

Commercial Services

Technology Services

Consumer Services

Finance

Consumer Services

Consumer Services

Consumer Services

Health Technology

Finance

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Jonathan Goldman